Anavex Life Sciences (AVXL) EBIT (2016 - 2025)
Anavex Life Sciences (AVXL) reported EBIT of -$5.7 million for Q4 2025, up 58.34% on a YoY basis from -$3.6 million in Q4 2024, and up 47.78% sequentially from -$10.8 million in Q3 2025.
Anavex Life Sciences (AVXL) EBIT (2016 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 10 years of EBIT data on file, last reported at -$5.7 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT rose 58.34% year-over-year to -$5.7 million; the trailing twelve-month figure through Dec 2025 stood at -$43.5 million (up 21.08% YoY), and the FY2025 full-year result was -$51.4 million, up 2.78% from the prior year.
- EBIT advanced to -$5.7 million in Q4 2025, from -$10.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $195.1 million in Q2 2021 to a low of -$15.4 million in Q4 2022.
- A 5-year average of $11.1 million and a median of -$12.6 million in 2024 frame the typical range for EBIT.
- Peak annual rise in EBIT reached 4315.69% in 2021, while the deepest fall reached 184.78% in 2021.
- Tracing AVXL's EBIT over 5 years: stood at -$11.7 million in 2021, then slumped by 31.22% to -$15.4 million in 2022, then rose by 26.04% to -$11.4 million in 2023, then slipped by 19.46% to -$13.6 million in 2024, then surged by 58.34% to -$5.7 million in 2025.
- Business Quant data shows AVXL's EBIT at -$5.7 million in Q4 2025, -$10.8 million in Q3 2025, and -$14.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | -5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.66 Mn |
| Sep 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -12.51 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -14.27 Mn |
| Jun 30, 2024 | -14.60 Mn |
| Mar 31, 2024 | -12.62 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -12.66 Mn |
| Jun 30, 2023 | -13.53 Mn |
| Mar 31, 2023 | -14.19 Mn |
| Dec 31, 2022 | -15.38 Mn |
| Sep 30, 2022 | -15.28 Mn |
| Jun 30, 2022 | -12.46 Mn |
| Mar 31, 2022 | -11.52 Mn |
| Dec 31, 2021 | -11.72 Mn |
| Sep 30, 2021 | 128.68 Mn |
| Jun 30, 2021 | 195.13 Mn |
| Mar 31, 2021 | 114.65 Mn |